Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists track COVID antibodies for two years to unlock immunity secrets

NCT ID NCT04750720

Knowledge-focused Sponsor: Centre Hospitalier Régional d'Orléans Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 187 people who had COVID-19 to see how their antibody levels changed over 24 months. Researchers took blood samples and, in some cases, nasal swabs to measure both general and neutralizing antibodies. They also looked at how the severity of the initial infection and vaccination affected antibody persistence. The goal is to better understand long-term immunity after COVID-19.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors predict how long COVID-19 immunity lasts and tailor vaccine schedules based on infection severity.
What could go wrong
This is an observational study, not a treatment trial. It only measures antibodies, which may not fully reflect protection. Results may not apply to new virus variants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

187 people

The number who actually took part.

Started

Aug 2020

Finished

Mar 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 * Having had a confirmed infection with CoV-2-SARS by RT-PCR and/or serology (IgM and/or IgG specific as significant) * Being vaccinated against anti-SARS-CoV-2 (vaccine sub-study) * Benefiting from a Social Security system * Having consented to participate in the study * Accepting regular follow-up for 24 months Exclusion Criteria: * Protected person (under guardianship or trusteeship) * Person under the protection of justice * Person unable to express consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 SARS-CoV 2

Contacts and locations

Locations

  • CHU Orléans

    Orléans, 45067, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.